Company Overview

Ansella Therapeutics is specialty pharmaceutical company that leverages biomimetic sciences to develop novel therapeutics that improve healthcare outcomes. The company’s initial focus is on women’s health, specifically in the development of novel vaginal formulations.

Biomimetics is an interdisciplinary field in which principles from engineering, chemistry and biology are applied to the synthesis of materials, or synthetic systems that have functions that mimic biological processes. Biomaterials are any natural or synthetic material that interacts with any part of a biological system. Biomimetic designs can be used in regenerative medicine, tissue engineering and drug delivery.

Ansella Therapeutics utilizes its expertise in materials science and biomedical engineering to create unique, enhanced therapeutic approaches inspired by inherent anatomy, physiology, biochemistry, and endocrinology.

The company has launched its first product, Cerynë Intimate Care, for women with everyday vaginal dryness and designed for vulvovaginal application. Cerynë Intimate Care is the world’s first biomimetic formulation which works with your body to restore comfort and balance.

Cerynë Intimate care has been launched both directly to consumers and through physician channels as an intimate care product for vaginal dryness.

Ansella Therapeutics is developing a range of treatment that focus on Women’s Health including Menopause, Vaginal mucositis, Endometriosis, Uterine Fibroids and vaginal Infection.

Company Overview

Caresyntax has developed an enterprise-grade surgical intelligence system that is vendor-neutral and equipped with proprietary software, hardware, and advanced AI capabilities. It can ingest and analyze data throughout the surgical workflow, including EMR, video, audio, image, device data, financial and outcomes data, and clinical and operational metrics to capture a complete picture of the surgical pathway. This allows the platform to generate insights across the entire continuum of care—before the procedure with surgical workflow optimization, during surgery with real-time clinically relevant support tools, and post procedure with clinical safety modules. The platform also produces data analytics and insights for medical device companies, insurers, and other ecosystem players to innovate and drive the future of healthcare delivery.
The Company has a footprint in 3,000 operating rooms, has been used in over 3 million surgeries, and has over 30,000 surgical users.

Company Overview

FluidAI is a healthcare technology company developing artificial intelligence–driven solutions to improve the management of fluid status in hospitalized patients. The company’s platform is designed to support earlier clinical decision making and reduce complications associated with fluid imbalance, a key driver of morbidity, length of stay, and healthcare costs.

FluidAI’s technology leverages continuous physiological data and advanced machine learning models to generate actionable insights for clinicians, enabling proactive intervention before adverse events occur. By integrating seamlessly into existing clinical workflows, the platform aims to enhance patient safety while improving efficiency in acute and critical care settings.

Addressing a large, global inpatient market with significant unmet need, FluidAI is positioned to benefit from growing demand for data-driven, preventative care solutions. The company’s approach aligns with health system priorities around outcome improvement, cost containment, and the adoption of clinically validated AI technologies.

Company Overview

Huma Therapeutics is revolutionizing healthcare by enabling remote patient monitoring and decentralized clinical trials through its advanced, condition-agnostic platforms. Huma’s mission is to shift healthcare from hospital-centric to home-centric, enabling proactive and personalized care. Its award-winning modular platforms are used by more than 3,000 hospitals and clinics, with over 35 million screened users and 4 million registered users in healthcare and has powered over 800 studies supporting about 1 million participants across research.
The Company is in high growth mode and actively pursuing both M&A and IPO options but isn’t looking to commit to either option at this point. The management believes that they have significant growth potential and will choose the appropriate exit path when it is optimum for their shareholders.